Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age

NCT04515147 is registered in ClinicalTrials.gov with CureVac as lead sponsor.

NCT NCT04515147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04515147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age
Lead sponsor
CureVac
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2020
Completion date
February 21, 2022
Enrollment
668 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid19, sars-cov-2, severe acute respiratory syndrome